SAN Stock Analysis: Sanofi | PA
Drug Manufacturers - General | PA, France | Market Cap: 85.626m EUR | 12M Return: -12.1% | FR0000120578 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 145M
EPS Trend: -2.8%
Qual. Beats: 1
Rev. Trend: 69.1%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Sanofi SA is a French multinational pharmaceutical company headquartered in Paris, engaged in the research, development, manufacture, and marketing of therapeutic solutions across immunology and inflammation, rare diseases neurology, oncology, and vaccines. The companys vaccine portfolio includes pediatric vaccines (polio, pertussis, Hib), hexavalent combination vaccines for hepatitis A, typhoid, yellow fever, and rabies, as well as Fluzone for influenza. Incorporated in 1994 and formerly known as Sanofi-Aventis until its 2011 rebranding, Sanofi operates as a large-cap pharmaceutical issuer listed on Euronext Paris.
Beyond its in-house pipeline, Sanofi pursues an extensive external innovation strategy, maintaining collaboration and licensing agreements with numerous biotechnology and artificial intelligence partners. These include deals with Exscientia, ABL Bio, Innate Pharma, Atomwise, Insilico Medicine, Kymera Therapeutics, Nurix Therapeutics, Denali Therapeutics, Adagene, Scribe Therapeutics, Teva Pharmaceuticals, and Provention Bio, spanning small-molecule discovery, protein degradation therapies, antibody-based treatments, genome editing, and AI-driven drug discovery. The pharmaceutical business model is characterized by high R&D expenditure, long development timelines, patent-driven revenue protection, and a growing reliance on partnership-based pipelines to supplement internal research capabilities.
- ixent sales surge on expanded COPD label approval
- Beyfortus RSV vaccine demand lifts vaccines segment growth
- Rare disease margins pressured by Pompe biosimilar competition
| Net Income: 6.76b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA -1.39 > 1.0 |
| NWC/Revenue: -0.85% < 20% (prev 16.96%; Δ -17.81% < -1%) |
| CFO/TA 0.13 > 3% & CFO 17.3b > Net Income 6.76b |
| Net Debt (19.1b) to EBITDA (13.8b): 1.39 < 3 |
| Current Ratio: 0.99 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.20b) vs 12m ago -2.77% < -2% |
| Gross Margin: 65.15% > 18% (prev 71.14%; Δ -5.99% > 0.5%) |
| Asset Turnover: 37.81% > 50% (prev 37.55%; Δ 0.26% > 0%) |
| Interest Coverage Ratio: 10.58 > 6 (EBIT TTM 8.31b / Interest Expense TTM 785.0m) |
| A: -0.00 (Total Current Assets 31.5b - Total Current Liabilities 31.9b) / Total Assets 129b |
| B: 0.49 (Retained Earnings 63.5b / Total Assets 129b) |
| C: 0.07 (EBIT TTM 8.31b / Avg Total Assets 127b) |
| D: 1.16 (Book Value of Equity 69.2b / Total Liabilities 59.5b) |
| Altman-Z'' = 3.24 = A |
| DSRI: 1.10 (Receivables 9.21b/8.21b, Revenue 48.0b/46.9b) |
| GMI: 1.09 (GM 71.14% / 65.15%) |
| AQI: 1.08 (AQ_t 0.66 / AQ_t-1 0.62) |
| SGI: 1.02 (Revenue 48.0b / 46.9b) |
| TATA: -0.08 (NI 6.76b - CFO 17.3b) / TA 129b) |
| Beneish M = -2.81 (Cap -4..+1) = A |
As of October 03, 2026, the stock is trading at EUR 70.81 with a total of 3,817,639 shares traded. Over the past week, the price has changed by -1.37%, over one month by -8.23%, over three months by -5.90% and over the past year by -12.08%.
Current recommended Stop Loss: 68.90 (which is 2.7% or 1.3 ATR below the current price).
Sanofi has no consensus analysts rating.
P/E Trailing = 22.1269
P/E Forward = 8.6281
P/S = 1.7504
P/B = 1.2878
P/EG = 28.7498
Revenue TTM = 48.0b EUR
EBIT TTM = 8.31b EUR
EBITDA TTM = 13.8b EUR
Long Term Debt = 14.6b EUR (from longTermDebt, last quarter)
Short Term Debt = 7.25b EUR (from shortTermDebt, last quarter)
Debt = 25.5b EUR (from shortLongTermDebtTotal, last quarter) + Leases 1.90b
Net Debt = 19.1b EUR (calculated: Debt 25.5b - CCE 6.35b)
Enterprise Value = 105b EUR (85.6b + Debt 25.5b - CCE 6.35b)
Interest Coverage Ratio = 10.58 (Ebit TTM 8.31b / Interest Expense TTM 785.0m)
EV/FCF = 6.36x (Enterprise Value 105b / FCF TTM 16.5b)
FCF Yield = 15.73% (FCF TTM 16.5b / Enterprise Value 105b)
FCF Margin = 34.32% (FCF TTM 16.5b / Revenue TTM 48.0b)
Net Margin = 14.08% (Net Income TTM 6.76b / Revenue TTM 48.0b)
Gross Margin = 65.15% ((Revenue TTM 48.0b - Cost of Revenue TTM 16.7b) / Revenue TTM)
Gross Margin QoQ = 75.47% (prev 72.09%)
Tobins Q-Ratio = 0.81 (Enterprise Value 105b / Total Assets 129b)
Interest Expense / Debt = 3.08% (Interest Expense 785.0m / Debt 25.5b)
Taxrate = 21.64% (1.88b / 8.70b)
NOPAT = 6.51b (EBIT 8.31b * (1 - 21.64%))
Current Ratio = 0.99 (Total Current Assets 31.5b / Total Current Liabilities 31.9b)
Debt / Equity = 0.37 (Debt 25.5b / totalStockholderEquity, last quarter 69.2b)
Debt / EBITDA = 1.39 (Net Debt 19.1b / EBITDA 13.8b)
Debt / FCF = 1.16 (Net Debt 19.1b / FCF TTM 16.5b)
Total Stockholder Equity = 71.7b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.32% (Net Income 6.76b / Total Assets 129b)
RoE = 9.43% (Net Income TTM 6.76b / Total Stockholder Equity 71.7b)
RoCE = 9.62% (EBIT 8.31b / Capital Employed (Equity 71.7b + L.T.Debt 14.6b))
RoIC = 6.38% (NOPAT 6.51b / Invested Capital 102b)
WACC = 5.07% (E(85.6b)/V(111b) * Re(5.86%) + D(25.5b)/V(111b) * Rd(3.08%) * (1-Tc(0.22)))
Discount Rate = 5.86% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -92.84 | Cagr: -1.88%
[DCF] Terminal Value 74.46% ; FCFF base≈17.0b ; Y1≈16.1b ; Y5≈15.1b
[DCF] Fair Price = 182.7 (EV 238b - Net Debt 19.1b = Equity 219b / Shares 1.20b; r=8.35% [WACC [floored]]; 5y FCF grow -6.86% → 2.50% )
EPS Correlation: -2.83 | EPS CAGR: -0.10% | SUE: 1.41 | # QB: 1
Revenue Correlation: 69.09 | Revenue CAGR: 5.13% | SUE: 1.07 | # QB: 1
EPS current Quarter (2026-09-30): EPS=2.88 | Chg30d=-0.39% | Revisions=-29% | Analysts=10
EPS current Year (2026-12-31): EPS=8.58 | Chg30d=+0.30% | Revisions=+22% | GrowthEPS=+9.6% | GrowthRev=+9.2%
EPS next Year (2027-12-31): EPS=9.08 | Chg30d=+0.33% | Revisions=+10% | GrowthEPS=+5.8% | GrowthRev=+6.3%
[Analyst] Revisions Ratio: +5% (up=9, down=8)